Space-time clustering of recently-diagnosed tuberculosis and impact of ART scale-up: Evidence from an HIV hyper-endemic rural South African population.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
24 07 2019
Historique:
received: 07 02 2019
accepted: 28 06 2019
entrez: 26 7 2019
pubmed: 26 7 2019
medline: 22 10 2020
Statut: epublish

Résumé

In HIV hyperendemic sub-Saharan African communities, particularly in southern Africa, the likelihood of achieving the Sustainable Development Goal of ending the tuberculosis (TB) epidemic by 2030 is low, due to lack of cost-effective and practical interventions in population settings. We used one of Africa's largest population-based prospective cohorts from rural KwaZulu-Natal Province, South Africa, to measure the spatial variations in the prevalence of recently-diagnosed TB disease, and to quantify the impact of community coverage of antiretroviral therapy (ART) on recently-diagnosed TB disease. We collected data on TB disease episodes from a population-based sample of 41,812 adult individuals between 2009 and 2015. Spatial clusters ('hotspots') of recently-diagnosed TB were identified using a space-time scan statistic. Multilevel logistic regression models were fitted to investigate the relationship between community ART coverage and recently-diagnosed TB. Spatial clusters of recently-diagnosed TB were identified in a region characterized by a high prevalence of HIV and population movement. Every percentage increase in ART coverage was associated with a 2% decrease in the odds of recently-diagnosed TB (aOR = 0.98, 95% CI:0.97-0.99). We identified for the first time the clear occurrence of recently-diagnosed TB hotspots, and quantified potential benefit of increased community ART coverage in lowering tuberculosis, highlighting the need to prioritize the expansion of such effective population interventions targeting high-risk areas.

Identifiants

pubmed: 31341191
doi: 10.1038/s41598-019-46455-7
pii: 10.1038/s41598-019-46455-7
pmc: PMC6656755
doi:

Substances chimiques

Anti-Retroviral Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

10724

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R01 AI124389
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD084233
Pays : United States

Références

PLoS One. 2017 Oct 13;12(10):e0181797
pubmed: 29028800
J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):104-8
pubmed: 26322671
BMC Med. 2018 Oct 18;16(1):193
pubmed: 30333043
Glob Health Action. 2014 Oct 29;7:25496
pubmed: 25377332
J Int AIDS Soc. 2017 Jul 18;20(1):21691
pubmed: 28782333
Soc Sci Med. 2016 Aug;163:144-56
pubmed: 27423295
Bull World Health Organ. 2010 Aug 1;88(8):593-600
pubmed: 20680124
PLoS One. 2013 Sep 17;8(9):e75466
pubmed: 24069418
PLoS Med. 2012;9(7):e1001270
pubmed: 22911011
Sci Rep. 2019 Jan 30;9(1):979
pubmed: 30700798
Int J Epidemiol. 2018 Apr 1;47(2):537-549
pubmed: 29300904
J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):263-9
pubmed: 21317585
Science. 2016 Aug 19;353(6301):731
pubmed: 27540141
Popul Health Metr. 2011 Aug 05;9:47
pubmed: 21819602
Public Health Action. 2016 Sep;6(3):164-168
pubmed: 27695678
J R Soc Interface. 2015 May 6;12(106):
pubmed: 25878131
Lancet Infect Dis. 2015 Sep;15(9):1066-1076
pubmed: 26112077
J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):164-174
pubmed: 28291049
AIDS Behav. 2018 Jul;22(7):2368-2379
pubmed: 29779162
Lancet. 2016 Oct 8;388(10053):1603-1658
pubmed: 27733283
S Afr Med J. 2010 Feb 03;100(3):146-7
pubmed: 20459930
Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19485-9
pubmed: 20974976
Lancet. 2013 Oct 5;382(9899):1183-94
pubmed: 23915882
S Afr Med J. 2018 Jul 25;108(8):12370
pubmed: 30182871
PLoS One. 2015 Apr 07;10(4):e0122514
pubmed: 25849558
Clin Infect Dis. 2019 Jun 18;69(1):159-166
pubmed: 30383204
Lancet Infect Dis. 2016 Feb;16(2):227-38
pubmed: 26867464
PLoS One. 2014 Jun 17;9(6):e99880
pubmed: 24937804
Science. 2013 Feb 22;339(6122):961-5
pubmed: 23430655
BMC Infect Dis. 2018 Sep 26;18(1):481
pubmed: 30257667
Int J Tuberc Lung Dis. 2018 Mar 1;22(3):287-293
pubmed: 29471906
J Int AIDS Soc. 2015 Sep 25;18:20240
pubmed: 26411694
Lancet. 2015 Dec 5;386(10010):2324-33
pubmed: 26515676
Bull World Health Organ. 2019 Jun 1;97(6):405-414
pubmed: 31210678
Am J Respir Crit Care Med. 2010 Oct 15;182(8):1080-5
pubmed: 20558626
J Health Econ. 2014 May;35:34-46
pubmed: 24595066
Science. 2013 Feb 22;339(6122):966-71
pubmed: 23430656
Int J Tuberc Lung Dis. 2017 Nov 1;21(11):1147-1154
pubmed: 29037295
Int J Epidemiol. 2009 Aug;38(4):1008-16
pubmed: 19261659
Lancet. 2012 Dec 8;380(9858):2029-43
pubmed: 23201214
Public Health Action. 2016 Dec 21;6(4):247-251
pubmed: 28123962
Trop Med Int Health. 2013 Aug;18(8):934-41
pubmed: 23731253
Arch Intern Med. 2003 May 12;163(9):1009-21
pubmed: 12742798
Lancet. 2016 Oct 8;388(10053):1459-1544
pubmed: 27733281
Int J Epidemiol. 2011 Apr;40(2):318-26
pubmed: 20154009
PLoS One. 2015 Apr 13;10(4):e0123345
pubmed: 25875851
Int J Tuberc Lung Dis. 2011 Jul;15(7):933-7
pubmed: 21682967
Int J Epidemiol. 2008 Oct;37(5):956-62
pubmed: 17998242
Public Health Action. 2014 Jun 21;4(2):113-5
pubmed: 26399210
Lancet. 2011 Jul 2;378(9785):57-72
pubmed: 21420161
Trop Med Int Health. 2016 Jan;21(1):101-107
pubmed: 26509352

Auteurs

Andrew Tomita (A)

Africa Health Research Institute, KwaZulu-Natal, South Africa. tomita@ukzn.ac.za.
KwaZulu-Natal Research Innovation and Sequencing (KRISP), College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa. tomita@ukzn.ac.za.
Centre for Rural Health, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa. tomita@ukzn.ac.za.

Catherine M Smith (CM)

Institute of Health Informatics, University College London, London, UK.

Richard J Lessells (RJ)

KwaZulu-Natal Research Innovation and Sequencing (KRISP), College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.

Alexander Pym (A)

Africa Health Research Institute, KwaZulu-Natal, South Africa.

Alison D Grant (AD)

Africa Health Research Institute, KwaZulu-Natal, South Africa.
School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa.
TB Centre, London School of Hygiene & Tropical Medicine, London, UK.
School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.

Tulio de Oliveira (T)

KwaZulu-Natal Research Innovation and Sequencing (KRISP), College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Department of Global Health, University of Washington, Seattle, USA.

Frank Tanser (F)

Africa Health Research Institute, KwaZulu-Natal, South Africa.
School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa.
Research Department of Infection & Population Health, University College London, London, UK.
Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH